Skip to main content
Premium Trial:

Request an Annual Quote

Theradiag Receives $1.6M to Develop Test Kits for HIV/AIDS, Obesity Project

NEW YORK (GenomeWeb News) – Theradiag today announced that Oséo has provided it €1.2 million ($1.6 million) to develop new diagnostic kits as part the French firm's participation in a project to develop RNA-targeting therapeutics and diagnostics aimed at HIV/AIDS and obesity.

Oséo, the French Agency for Innovation, is providing funding to Theradiag for work that will be done as part of its participation in CaReNA, a collaboration among drug development firm Splicos, Theradiag, and the French National Center for Research and Science.

Theradiag, a theranostics and in vitro diagnostics company, will develop four new diagnostics kits, including two companion diagnostic tests for therapies from Splicos. One CDx will be for Splicos' therapy for treating HIV/AIDS, the other is for monitoring diabetes and associated metabolic disorders.

These tests will be implemented during the clinical development phases, Theradiag said, allowing physicians to optimize care of their patients.

Theradiag will also develop a test for the early monitoring of HIV infection and disease evolution, and a fourth test will be aimed at assessing patient response and/or resistance to antiretroviral treatments by quantifying predictive miRNAs.

"This new financing will allow us to expand our theranostic range with four new molecular biology/miRNA diagnostic kits, adding on to the existing seven blood-test kits of the Lisa Tracker portfolio," Theradiag's multiparameter diagnosis solution for patients with autoimmune diseases treated with biotherapies, Theradiag CEO Michel Finance said in a statement.

"With these new kits, we will be able to tap into the broad diagnostic markets of HIV/AIDS and metabolic disorders," Finance added.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.